68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy-Reference-Cited by-同舟云学术

68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy

Published:2017-07 Issue:13 Volume:12 Page:1561-1574
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Bouziotis Penelope¹,Stellas Dimitris²,Thomas Eloïse³,Truillet Charles³,Tsoukalas Charalampos¹,Lux François³,Tsotakos Theodoros¹,Xanthopoulos Stavros¹,Paravatou-Petsotas Maria¹,Gaitanis Anastasios²,Moulopoulos Lia Angela⁴,Koutoulidis Vassilis⁴,Anagnostopoulos Constantinos D²,Tillement Olivier³

Affiliation:

1. Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research ‘Demokritos,’ Aghia Paraskevi 15310, Athens, Greece

2. Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece

3. Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon, 69622 Villeurbanne cedex, France

4. First Department of Radiology, School of Medicine, National & Kapodistrian University of Athens, 76 Vasilissis Sofias Avenue, 11528, Athens, Greece

Abstract

Aim: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga). Materials & methods: AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging. Results: 68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection. Conclusion: This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2017-0032

Reference36 articles.

1. First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses

2. Development and in vivo imaging of a PET/MRI nanoprobe with enhanced NIR fluorescence by dye encapsulation

3. PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoprobes for PET/MR Imaging;Advanced Therapeutics;2023-11-14

2. Liquid Metal Biomedical Imaging;Handbook of Liquid Metals;2023-10-31

3. Nanoparticles for MRI-guided radiation therapy: a review;Cancer Nanotechnology;2022-11-12

4. Methods for Radiolabelling Nanoparticles: PET Use (Part 2);Biomolecules;2022-10-20

5. Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis;The Chemical Record;2022-02-10